Preclinical development of virus‐like particle (VLP)‐based immunotherapy against house dust mite allergy

Documenti analoghi

• Immunotherapeutic effects of specific and nonspecific mRNA‐lipid nanoparticles in a mouse model of HDM‐induced airway inflammation
  di: Chanatip Thanasarnthungcharoen, et al.
  Pubblicazione: (2024)
• Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis
  di: Nan Wang, et al.
  Pubblicazione: (2024)
• One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable
  di: M. Jutel, et al.
  Pubblicazione: (2024)
• Systemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real‐life, multi‐center study
  di: Qingxiu Xu, et al.
  Pubblicazione: (2024)
• Correction to “Increase in the prevalence of follicular regulatory T cells correlates with clinical efficacy of sublingual immunotherapy with house dust mites”
  Pubblicazione: (2024)